In a study of identical twins, a team led by PD Dr. Lisa Ann Gerdes (Institute of Clinical Neuroimmunology at LMU University ...

Stimulating a key metabolic pathway in T cells can make them work more effectively against tumors when combined with immune checkpoint inhibitor therapy, according to a preclinical study. The findings ...

PD-1是CD28家族的一员，在多种免疫细胞中表达，特别是外周组织中活化的CD8+T细胞、CD4+T细胞和B细胞中[2]。PD-1有两个结合配体，PD-L1(B7-H1或CD274 ...

By Susha Cheriyedath, M.Sc. Researchers discover a novel protein therapy that recharges exhausted T cells, unleashing their ...

Researchers have discovered that combining immunotherapy and chemotherapy can overcome treatment resistance in a subset of ...

*仅供医学专业人士阅读参考把肿瘤微环境内因抗原慢性刺激转入耗竭状态的CD8+T细胞“叫醒”，让它们重新活化为效应CD8+T细胞，是PD-1/L1抑制剂为代表的现有免疫治疗起效的关键，但实话实说，激活处在耗竭状态的CD8+T细胞，在奇点糕眼里总觉得有点 ...

Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that patients with metastatic ...

10 年前，他是基因泰克/罗氏公司生物信息首席科学家，10 年后的今天，他是北京大学生物医学前沿创新中心（BIOPIC）中心主任，他的一生都致力于用前沿的生物信息和基因组学来解决癌症生物学中的核心问题，专注于研究肿瘤微环境的底层特征。张泽民院士，作为肿瘤与生物信息领域的领军人物，在 2024 年发表了不少代表性的文章，今天笔者就同大家从一篇 Cell 文章开始，一起领略一下张泽民院士在 2024 ...

*仅供医学专业人士阅读参考在目前已经获批的各种免疫联合治疗方案里，PD-1/L1抑制剂和CTLA-4抑制剂组成的“双免疫方案”，经常给奇点糕一种双刃剑的感觉，一方面它们确实取得了不少关键临床研究的成功，对非小细胞肺癌（NSCLC）、肝癌等常见实体瘤有 ...

T cells and other immune cells, when active, eventually start to express immune-suppressing checkpoint proteins such as PD-1, which are thought ... called cytotoxic CD8 + T cells.